Walleye Capital
ACOR

Walleye Capital’s Acorda Therapeutics ACOR Stock Holding History

Walleye Capital’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-52
Closed -$13K – 1875
2019
Q4 		$13K Sell
52
-373
-88% -$94.1K ﹤0.01% 1638
2019
Q3 		$146K Sell
425
-129
-23% -$70.1K 0.01% 1316
2019
Q2 		$510K Buy
+554
New +$681K 0.06% 481

Other funds holding ACOR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Walleye Capital's ACOR Position: Q1 2020 in Review

Walleye Capital sold out of Acorda Therapeutics (ACOR) in Q1 2020, closing a stake of 52 shares — an estimated $13K sold.

Walleye Capital first reported a position in ACOR in Q2 2019 and held it in 3 quarters. The position peaked at $510K in Q2 2019. 106 funds tracked by Wall St. Rank hold ACOR as of Q1 2020.

  • Walleye Capital reported no remaining Acorda Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Walleye Capital sold 52 Acorda Therapeutics shares in Q1 2020, an estimated $13K.
  • Walleye Capital first reported a position in Acorda Therapeutics in Q2 2019 and held it in 3 quarters.
  • Walleye Capital's Acorda Therapeutics position peaked at $510K in Q2 2019.
  • 106 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q1 2020.

Based on Walleye Capital's 13F filing for Q1 2020, filed 15 May 2020.